Cost-effectiveness analysis of active psoriatic arthritis treatment with ixekizumab in adult patients in Russian Federation health care system
Objective: to evaluate the economic impact of the use of various biologic disease-modifying antirheumatic drugs (bDMARDs) from the group of inhibitors of interleukins (iIL) 12/23 and iIL17 in adult patients with psoriatic arthritis (PsA) with insufficient response to therapy with TNFα inhibitors (TN...
Saved in:
Main Authors: | E. A. Pyadushkina, E. V. Derkach, M. Yu. Frolov, V. A. Rogov, A. S. Salasyuk |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2021-02-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/1110 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibitors of interleukin 17A in the treatment of psoriatic arthritis: what's new?
by: Т. V. Korotaeva
Published: (2021-04-01) -
Successful use of the interleukin-17A inhibitor (ixekizumab) in the treatment of psoriatic arthritis
by: A. M. Dadalova, et al.
Published: (2020-11-01) -
Ixekizumab in the treatment of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2024-12-01) -
The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice
by: I. M. Marusenko, et al.
Published: (2021-06-01) -
Clinical experience of using Ixekizumab in treatment of a female patient with severe psoriasis and psoriatic arthritis, resistant to the therapy
by: N. V. Kungurov, et al.
Published: (2021-06-01)